BioCryst slides on revised peramivir study, lack of funds
This article was originally published in Scrip
Shares of BioCryst Pharmaceuticals fell as low as 10.4%, or 54 cents, on the NASDAQ 13 January after the firm said it would need additional funding from the US Biomedical Advanced Research & Development Authority (BARDA) to complete an ongoing, multicentre, randomised, double-blind, controlled study to evaluate the efficacy and safety of its intravenous antiviral peramivir. The news overshadowed more positive news of top-line data from another Phase III trial of the antiviral.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.